Versartis, Inc. (VSAR) Holdings Cut by New York State Common Retirement Fund

New York State Common Retirement Fund cut its position in Versartis, Inc. (NASDAQ:VSAR) by 0.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,415 shares of the biopharmaceutical company’s stock after selling 1 shares during the quarter. New York State Common Retirement Fund owned about 0.19% of Versartis worth $1,176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Emory University purchased a new stake in Versartis in the 2nd quarter worth approximately $1,709,000. Credit Suisse AG lifted its stake in Versartis by 28.0% in the 1st quarter. Credit Suisse AG now owns 27,066 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 5,917 shares in the last quarter. Teachers Advisors LLC lifted its stake in Versartis by 9.7% in the 1st quarter. Teachers Advisors LLC now owns 55,244 shares of the biopharmaceutical company’s stock worth $1,179,000 after purchasing an additional 4,876 shares in the last quarter. Vanguard Group Inc. lifted its stake in Versartis by 11.3% in the 1st quarter. Vanguard Group Inc. now owns 1,002,507 shares of the biopharmaceutical company’s stock worth $21,404,000 after purchasing an additional 101,578 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its stake in Versartis by 63.1% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 288,960 shares of the biopharmaceutical company’s stock worth $5,042,000 after purchasing an additional 111,824 shares in the last quarter. Institutional investors and hedge funds own 73.61% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Versartis, Inc. (VSAR) Holdings Cut by New York State Common Retirement Fund” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/02/versartis-inc-vsar-holdings-cut-by-new-york-state-common-retirement-fund.html.

Versartis (NASDAQ:VSAR) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period in the previous year, the firm earned ($0.92) EPS.

In other news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the business’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $3.29, for a total value of $7,007,700.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 2,132,769 shares of company stock worth $7,014,761 in the last three months. Insiders own 10.90% of the company’s stock.

VSAR has been the topic of several research reports. ValuEngine cut shares of Versartis from a “sell” rating to a “strong sell” rating in a research report on Friday, September 22nd. Cantor Fitzgerald set a $34.00 price objective on shares of Versartis and gave the company a “buy” rating in a research report on Thursday, July 27th. Zacks Investment Research upgraded shares of Versartis from a “sell” rating to a “hold” rating in a research report on Wednesday, August 30th. SunTrust Banks, Inc. cut shares of Versartis from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $4.00 in a research report on Friday, September 22nd. Finally, Canaccord Genuity restated a “buy” rating and set a $9.00 price objective (down previously from $28.00) on shares of Versartis in a research report on Friday, September 22nd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. Versartis presently has an average rating of “Hold” and a consensus price target of $7.22.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis, Inc. (NASDAQ:VSAR).

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply